We just received data on a new analyst forecast for $HIMS. Citigroup gave a rating of 'Sell' for $HIMS.
$HIMS Analyst Ratings
Wall Street analysts have issued reports on $HIMS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Sell" rating on 06/23/2025
- UBS issued a "Underperform" rating on 06/23/2025
- Needham issued a "Buy" rating on 06/04/2025
- Canaccord Genuity issued a "Buy" rating on 02/19/2025
To track analyst ratings and price targets for $HIMS, check out Quiver Quantitative's $HIMS forecast page.
$HIMS Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 3 analysts offer price targets for $HIMS in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Jailendra Singh from Truist Financial set a target price of $45.0 on 06/24/2025
- An analyst from UBS set a target price of $30.0 on 06/23/2025
- Ryan Macdonald from Needham set a target price of $65.0 on 06/04/2025
$HIMS Insider Trading Activity
$HIMS insiders have traded $HIMS stock on the open market 128 times in the past 6 months. Of those trades, 0 have been purchases and 128 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- ANDREW DUDUM (Chief Executive Officer) has made 0 purchases and 48 sales selling 1,247,836 shares for an estimated $55,402,280.
- MELISSA BAIRD (Chief Operating Officer) has made 0 purchases and 25 sales selling 303,064 shares for an estimated $11,008,819.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 15 sales selling 362,976 shares for an estimated $10,884,870.
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 20 sales selling 143,086 shares for an estimated $5,464,872.
- MICHAEL CHI (Chief Commercial Officer) has made 0 purchases and 12 sales selling 88,842 shares for an estimated $4,061,254.
- IRENE BECKLUND (PAO) has made 0 purchases and 7 sales selling 32,088 shares for an estimated $1,411,579.
- PATRICK HARRISON CARROLL (Chief Medical Officer) sold 23,287 shares for an estimated $798,976
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$HIMS Hedge Fund Activity
We have seen 252 institutional investors add shares of $HIMS stock to their portfolio, and 249 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 5,862,886 shares (-19.5%) from their portfolio in Q1 2025, for an estimated $173,248,281
- D. E. SHAW & CO., INC. added 5,390,213 shares (+841.7%) to their portfolio in Q1 2025, for an estimated $159,280,794
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 4,332,982 shares (-68.7%) from their portfolio in Q1 2025, for an estimated $128,039,618
- SRS INVESTMENT MANAGEMENT, LLC added 4,000,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $118,200,000
- ICONIQ CAPITAL, LLC removed 2,874,769 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $84,949,423
- GOLDMAN SACHS GROUP INC added 2,738,501 shares (+49.4%) to their portfolio in Q1 2025, for an estimated $80,922,704
- INSTITUTIONAL VENTURE MANAGEMENT XV, LLC removed 2,597,558 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $62,808,952
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
